The Next-Generation Of Precision-Guided Therapeutics

Specific Tissue Delivery Remains a Major Challenge that Impacts Both Efficacy and Safety



Single domain Antibodies have been a Major Breakthrough Unlocking Tissue Delivery



~ 12 - 15 kDa

Single domain antibodies

(sdAb)

V-Bodies

Camelid-

sdAb

Our V-Body Platform Addresses Some of the Limitations of sdAbs...



V-bodies

~ 15 kDa



lgG

(mAb)

Fab

scFv

Peptide

... Through Three Unique and Key Attributes



Our Proprietary Platform Allows Significant Time Saving to Generate an Optimal and Customized V-Body

1 - 2 Fully synthetic humanized VHH or human VH V-Body libraries 2 – Proprietary scaffolds with random CDRs and 4 different lengths of CDR3

3 – Rationale design of CDR regions to create billions of different versions of the V-Bodies

Valerio Therapeutics



Generate diversity:

« GimLi » library: 1.6x10^9 Human VH (sdAb) « NaLi » library: 3x10^9 Humanized Lama VHH (sdAb)

Generate refined affinity:

In vitro selection methods – V-Bodies in pM-nM ranges suitable for therapeutic development

Bypassing immunological conservation

A fully *in vitro* process in less than 2 months

Unparalleled *In Vitro* Selection Process Allowing for Tailor-Made Functional Binders



V-Select



(>100 peer reviewed publications)

Harnessing Capabilities Allowing for a State of the Art Integrated Process from A to Z...



... and Derisking Next-Generation Drug Candidate for FIH in Less than 2 Years



Benefits are Already Materialized by a Diversified Pipeline Generating Increasing Interest from Industry



We Aim to Bring Precision-Guided Therapeutics to a New Level

